SCHEMBL6920968

SCHEMBL6920968

CN1CCn2c(nc3cc(-c4ccccn4)ccc3c2=O)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
TDP1 Q9NUW8 2/20 0.42
CYP3A4 P08684 1/20 0.42
NSD2 O96028 1/20 0.41
TGFBR1 P36897 1/20 0.41
METAP1 P53582 1/20 0.41
LMNA P02545 2/20 0.40
CYP2C19 P33261 1/20 0.40
TACR3 P29371 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
USP2 O75604 1/20 0.39
CYP1A2 P05177 1/20 0.39
BCHE P06276 1/20 0.39
CFTR P13569 1/20 0.39
ALOX15 P16050 1/20 0.39
ACHE P22303 1/20 0.39
HKDC1 Q2TB90 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6922679 0.84 PRMT5 (0.43) NPC1RAB9ATDP1CYP3A4NSD2
SCHEMBL12059616 0.83 NPC1 (0.42) NPC1RAB9ATDP1CYP3A4NSD2
SCHEMBL6922198 0.83 ALDH1A1 (0.60) NPC1RAB9ATDP1NSD2TGFBR1
SCHEMBL12059328 0.82 MEN1 (0.60) NPC1RAB9ATDP1NSD2LMNA
SCHEMBL12059670 0.82 CYP3A4 (0.40) NPC1RAB9ATDP1CYP3A4NSD2
SCHEMBL6921502 0.82 CYP3A4 (0.40) NPC1RAB9ATDP1CYP3A4NSD2
SCHEMBL6922859 0.81 NPC1 (0.39) NPC1RAB9ATDP1CYP3A4NSD2
SCHEMBL12059030 0.81 NPC1 (0.42) NPC1RAB9ATDP1CYP3A4NSD2
SCHEMBL12059187 0.81 NPC1 (0.44) NPC1RAB9ATDP1CYP3A4NSD2
SCHEMBL6922421 0.81 NPC1 (0.48) NPC1RAB9ATDP1CYP3A4NSD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof SUNOVION PHARMACEUTICALS INC. (US) 2011-12-29 US disclosed
WO-2011075699-A2 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof GRM5, GRM2, GRM1 NPC1 811/4885RAB9A 1387/4885TDP1 1917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.